Remo Panaccione

ORCID: 0000-0002-5247-940X · 3 papers in corpus
observational 2025
US and European Patient and Health Care Professional Perspectives on Fatigue in Ulcerative Colitis and Crohn's Disease: Results From the Communicating Needs and Features of Inflammatory Bowel Disease Experiences Survey
Crohn's & colitis 360 ·doi:10.1093/crocol/otaf011

BACKGROUND: Fatigue is a burdensome symptom of Crohn's disease (CD) and ulcerative colitis (UC). The Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study investigated how patients and health care profes…

nonrandomized-trial 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study.
Inflammatory bowel diseases ·doi:10.1093/ibd/izae024

BackgroundMirikizumab, a p19-directed interleukin-23 monoclonal antibody, is efficacious in inducing clinical remission at week 12 (W12) and maintaining clinical remission at W52 in patients with moderately to severely active ulcerative col…

observational 2018
Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
Therapeutic advances in gastroenterology ·doi:10.1177/1756284818783614

BACKGROUND: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn's disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this stu…